NASDAQ$MDGL
Madrigal Pharmaceuticals Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Madrigal reported financial results for Q4 2019 and highlighted progress in executing its business strategy and advancing the development of resmetirom.
Madrigal Pharmaceuticals reported a net loss of $27.74 million for the fourth quarter of 2019, with operating expenses totaling $30.0 million, driven primarily by increased research and development expenses related to Phase 3 studies. As of December 31, 2019, the company's cash, cash equivalents, and marketable securities amounted to $439.0 million.
- Madrigal initiated two Phase 3 studies in NASH: MAESTRO-NASH and MAESTRO-NAFLD-1.
- The company expanded its medical operations team and added Jim Daly to its Board.
- Madrigal believes it has sufficient financial resources to fund its two ongoing Phase 3 clinical studies.
- Both Phase 3 studies are on track to complete enrollment this year for the 52 week readout by the end of 2021.
Headline financials
Revenue & EPS history
Madrigal · Revenue · Quarterly
$311M
Forward guidance
Madrigal is focused on the clinical development of resmetirom and anticipates completing enrollment for its Phase 3 studies, MAESTRO-NASH and MAESTRO-NAFLD-1, with a 52-week readout expected by the end of 2021.
Tailwinds
- Phase 3 studies MAESTRO-NASH and MAESTRO-NAFLD-1 are on track for enrollment completion in 2020.
- 52-week readout from Phase 3 studies expected by the end of 2021.
- MAESTRO-NAFLD-1 includes an open label active treatment arm providing data on lipids and non-invasive NASH biomarkers in 2020.
- Resmetirom has the potential to resolve NASH and reduce liver fibrosis.
- Resmetirom may decrease cardiovascular risk through reduction of atherogenic lipids.
Headwinds
- Clinical development of resmetirom is subject to enrollment uncertainties.
- Outcomes from competitive studies could impact resmetirom's prospects.
- Achieving potential benefits in larger studies carries inherent risks.
- Timing and outcomes of resmetirom's clinical studies are uncertain.
- Clinical testing inherently involves uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.6%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+7.8%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+48.0%
Q3 2024
Best reaction
-23.3%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -1.2% | -3.2% | |
| Q4 2025 | -11.1% | -10.5% | -10.2% | |
| Q3 2025 | +7.8% | +18.7% | +42.2% | |
| Q1 2025 | -1.9% | -11.6% | -17.6% | |
| Q4 2024 | +15.0% | +1.3% | +5.9% | |
| Q3 2024 | +48.0% | +56.4% | +52.0% | |
| Q2 2024 | -8.6% | -9.2% | -8.5% | |
| Q1 2024 | -11.7% | -12.9% | +2.5% | |
| Q4 2023 | -1.5% | +2.8% | +11.4% | |
| Q3 2023 | +3.6% | -5.5% | +61.1% | |
| Q2 2023 | -6.0% | -4.5% | +6.4% | |
| Q1 2023 | -5.4% | -5.2% | -12.8% | |
| Q4 2022 | -5.4% | -7.1% | -19.6% | |
| Q3 2022 | -6.7% | -10.1% | +12.8% | |
| Q2 2022 | +22.8% | +12.1% | +10.8% | |
| Q1 2022 | -0.2% | +1.8% | +15.0% | |
| Q4 2021 | +7.9% | +13.1% | +9.2% | |
| Q3 2021 | -0.5% | -1.6% | -16.6% | |
| Q2 2021 | +7.5% | +0.8% | -4.5% | |
| Q1 2021 | +0.7% | +2.3% | -22.0% | |
| Q4 2020 | -1.3% | -6.9% | -5.3% | |
| Q3 2020 | -6.8% | -2.2% | -10.9% | |
| Q2 2020 | -1.1% | -2.2% | +2.3% | |
| Q1 2020 | +2.9% | +25.1% | +27.6% | |
| Q4 2019 | -2.5% | +2.6% | -19.7% | |
| Q3 2019 | +0.1% | +7.9% | +22.1% | |
| Q2 2019 | +2.0% | +2.0% | +9.8% | |
| Q1 2019 | +0.2% | -3.4% | -8.0% | |
| Q4 2018 | -2.4% | +3.1% | -6.9% | |
| Q3 2018 | +5.2% | -7.8% | -39.7% | |
| Q2 2018 | -1.0% | -5.9% | -11.0% | |
| Q1 2018 | -0.0% | +2.2% | +138.3% | |
| Q4 2017 | -16.4% | -20.4% | -15.8% | |
| Q3 2017 | -0.2% | -5.7% | +84.7% | |
| Q2 2017 | -0.8% | +1.7% | +13.5% | |
| Q1 2017 | +2.1% | +4.5% | -0.3% | |
| Q4 2016 | -2.2% | -4.9% | +6.8% | |
| Q3 2016 | +5.3% | +2.4% | -1.4% | |
| Q2 2016 | +3.8% | +11.5% | +1.9% | |
| Q1 2016 | +10.5% | — | — | |
| Q4 2015 | -23.3% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | -3.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | -6.1% | — | — | |
| Q3 2014 | +10.6% | — | — | |
| Q2 2014 | +0.5% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | -10.1% | — | — | |
| Q3 2013 | +0.9% | — | — | |
| Q2 2013 | -4.2% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | -5.0% | — | — | |
| Q3 2012 | -5.2% | — | — | |
| Q2 2012 | +0.3% | — | — | |
| Q1 2012 | -11.2% | — | — | |
| Q4 2011 | +0.2% | — | — | |
| Q4 2009 | +0.2% | — | — | |
| Q3 2011 | +4.4% | — | — | |
| Q2 2011 | -10.1% | — | — | |
| Q4 2010 | -10.1% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q3 2010 | -6.1% | — | — | |
| Q2 2010 | -5.6% | — | — | |
| Q1 2010 | -16.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro